<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879928</url>
  </required_header>
  <id_info>
    <org_study_id>FM101-CTP1-001</org_study_id>
    <nct_id>NCT03879928</nct_id>
  </id_info>
  <brief_title>A SAD, MAD, and FE Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of FM101 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Alternating Panel Single Ascending Dose, Sequential Multiple Ascending Dose, and Food Effect Study of FM101 in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Future Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Future Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a double blind, randomized, placebo controlled, single and multiple ascending dose&#xD;
      (SAD/MAD) study in healthy subjects. Safety evaluation will include adverse events (TEAEs),&#xD;
      clinical laboratory values, vital signs, ECGs, and physical examinations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study in healthy volunteers designed&#xD;
      to assess the safety, tolerability and PK of FM101. This study will consist of 3 parts: a SAD&#xD;
      part, a single dose FE part and a MAD part. Each subject is to participate in only 1 part of&#xD;
      the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of FM101 after SAD and MAD doses to healthy volunteers by assessing the number, severity, and type of TEAEs.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of TEAEs (frequency of occurrence, number of subjects experiencing the event)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the change in clinical laboratory values from the baseline after SAD and MAD doses.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of abnormalities with clinical significance (frequency of occurrence, number of subjects experiencing the event)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the change in vital signs from the baseline after SAD and MAD doses.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of abnormalities with clinical significance (frequency of occurrence, number of subjects experiencing the event)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the change in electrocardiograms (ECGs) after SAD and MAD doses.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of abnormalities with clinical significance (frequency of occurrence, number of subjects experiencing the event).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the change in physical examinations after SAD and MAD doses.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of abnormalities with clinical significance (frequency of occurrence, number of subjects experiencing the event).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess maximum observed plasma concentration (Cmax) following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>Cmax of FM101 in plasma will be calculated as applicable:&#xD;
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess area under plasma concentration-time curve from hour 0 to last sample following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>AUClast of FM101 in plasma will be calculated as applicable:&#xD;
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess area under plasma concentration-time curve from hour 0 to infinity following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>AUCinf of FM101 in plasma will be calculated as applicable:&#xD;
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess time to reach the maximum concentration in plasma (Tmax) following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>Tmax of FM101 in plasma will be calculated as applicable:&#xD;
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess terminal elimination rate constant (Kel) following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>Kel of FM101 in plasma will be calculated as applicable:&#xD;
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess terminal half-life (t1/2) following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>t1/2 of FM101 in plasma will be calculated as applicable: SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma Cmax of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>Cmax of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma AUClast of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>AUClast of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma AUCinf of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>AUCinf of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma Tmax of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>Tmax of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma Kel of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>Kel of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma t1/2 of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>t1/2 of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Urine concentrations of FM101 in MAD cohort 2</measure>
    <time_frame>MAD phase - At pre-dose (within 12 hours prior to dosing), and over 0-6, 6-12, 12-18, and 18-24 hours post-dose collection intervals on Day 1 and Day 7.</time_frame>
    <description>Cmax of FM101 in the urine will be calculated. MAD phase - cohort 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine concentrations of M6, FM101's metabolite in MAD cohort 2</measure>
    <time_frame>MAD phase - At pre-dose (within 12 hours prior to dosing), and over 0-6, 6-12, 12-18, and 18-24 hours post-dose collection intervals on Day 1 and Day 7.</time_frame>
    <description>Cmax of M6 in the urine will be calculated. MAD phase - cohort 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations of M6 in MAD cohort 2</measure>
    <time_frame>MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>Cmax of the plasma M6 will be calculated. MAD phase - cohor 2</description>
  </other_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Placebo for SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator for SAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 75 mg for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 150 mg for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 300 mg for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 600 mg for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 1200 mg for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 2400 mg for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator for MAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 150 mg (QD) for MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 450 mg (QD) for MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 600 mg (BID) for MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 300 mg under fasted condition for FE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food Effect of FM101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 300 mg under fed condition for FE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food Effect of FM101</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single ascending doses of FM101</intervention_name>
    <description>The study drug (FM101 and placebo comparator) will be administered orally as SAD doses</description>
    <arm_group_label>FM101 1200 mg for SAD</arm_group_label>
    <arm_group_label>FM101 150 mg for SAD</arm_group_label>
    <arm_group_label>FM101 2400 mg for SAD</arm_group_label>
    <arm_group_label>FM101 300 mg for SAD</arm_group_label>
    <arm_group_label>FM101 600 mg for SAD</arm_group_label>
    <arm_group_label>FM101 75 mg for SAD</arm_group_label>
    <arm_group_label>Placebo for SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple ascending doses of FM101</intervention_name>
    <description>The study drug (FM101 and placebo comparator) will be administered orally as MAD doses</description>
    <arm_group_label>FM101 150 mg (QD) for MAD</arm_group_label>
    <arm_group_label>FM101 450 mg (QD) for MAD</arm_group_label>
    <arm_group_label>FM101 600 mg (BID) for MAD</arm_group_label>
    <arm_group_label>Placebo for MAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Food effects of FM101</intervention_name>
    <description>The study drug (FM101) will be administered orally under fasted condition and fed condition.</description>
    <arm_group_label>FM101 300 mg under fasted condition for FE</arm_group_label>
    <arm_group_label>FM101 300 mg under fed condition for FE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gender: male or female&#xD;
&#xD;
          -  Age: 18 - 50 years, inclusive, at screening&#xD;
&#xD;
          -  Body mass index (BMI) : 18.0 - 32.0 kg/m2 (inclusive)&#xD;
&#xD;
          -  Weight : â‰¥ 50 kg&#xD;
&#xD;
          -  Status : healthy subjects&#xD;
&#xD;
          -  At screening, females must be non-pregnant and non-lactating, or of non child-bearing&#xD;
             potential (either surgically sterilized or physiologically incapable of becoming&#xD;
             pregnant, or at least 1 year post menopausal [amenorrhea duration of 12 consecutive&#xD;
             months); non-pregnancy will be confirmed for all females by a serum pregnancy test&#xD;
             conducted at screening, and a urine pregnancy test at each admission and at follow-up.&#xD;
&#xD;
          -  Female subjects of child-bearing potential, with a fertile male sexual partner, must&#xD;
             agree to use adequate contraception from screening until 90 days after the follow up&#xD;
             visit. Adequate contraception is defined as using hormonal contraceptives or an&#xD;
             intrauterine device combined with at least 1 of the following forms of contraception:&#xD;
             a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with&#xD;
             the lifestyle of the subject, is acceptable.&#xD;
&#xD;
          -  Male subjects, if not surgically sterilized, must agree to use adequate contraception&#xD;
             and not donate sperm from first admission to the clinical research center until 90&#xD;
             days after the follow-up visit. Adequate contraception for the male subject (and his&#xD;
             female partner) is defined as using hormonal contraceptives or an intrauterine device&#xD;
             combined with at least 1 of the following forms of contraception: a diaphragm or&#xD;
             cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of&#xD;
             the subject is acceptable.&#xD;
&#xD;
          -  All prescribed medication must have been stopped at least 14 days prior to (each)&#xD;
             admission to the clinical research center. An exception is made for hormonal&#xD;
             contraceptives, which may be used throughout the study.&#xD;
&#xD;
          -  All over-the-counter medication, vitamin preparations and other food supplements, or&#xD;
             herbal medications (eg, St. John's Wort) must have been stopped at least 7 days prior&#xD;
             to (each) admission to the clinical research center. An exception is made for&#xD;
             paracetamol, which is allowed up to admission to the clinical research center.&#xD;
&#xD;
          -  Ability and willingness to abstain from alcohol, methylxanthine-containing beverages&#xD;
             or food (coffee, tea, cola, chocolate, energy drinks), grapefruit (juice), and tobacco&#xD;
             products from 48 hours prior to (each) admission to the clinical research center.&#xD;
&#xD;
          -  Good physical and mental health on the basis of medical history, physical examination,&#xD;
             clinical laboratory, ECG, and vital signs, as judged by the Investigator.&#xD;
&#xD;
          -  Willing and able to sign the ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Employee of CRO or the Sponsor.&#xD;
&#xD;
          -  History of relevant drug and/or food allergies.&#xD;
&#xD;
          -  Using tobacco products within 60 days prior to (the first) drug administration.&#xD;
&#xD;
          -  History of alcohol abuse or drug addiction (including soft drugs like cannabis&#xD;
             products).&#xD;
&#xD;
          -  Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including&#xD;
             ecstasy], cannabinoids, barbiturates, benzodiazepines, gamma hydroxybutyric acid&#xD;
             [GHB], tricyclic antidepressants, and alcohol) at screening and (each) admission to&#xD;
             the clinical research center.&#xD;
&#xD;
          -  Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals&#xD;
             approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits).&#xD;
&#xD;
          -  Positive screen for hepatitis B surface antigen (HBsAg), anti hepatitis C virus (HCV)&#xD;
             antibodies, or anti human immunodeficiency virus (HIV) 1 and 2 antibodies.&#xD;
&#xD;
          -  Participation in a drug study within 60 days prior to (the first) drug administration&#xD;
             in the current study. Participation in more than 3 other drug studies (for male&#xD;
             subjects) / more than 2 other drug studies (for female subjects) in the 10 months&#xD;
             prior to (the first) drug administration in the current study.&#xD;
&#xD;
          -  Donation or loss of more than 100 mL of blood within 60 days prior to (the first) drug&#xD;
             administration. Donation or loss of more than 1.5 liters of blood (for male subjects)&#xD;
             / more than 1.0 liters of blood (for female subjects) in the 10 months prior to (the&#xD;
             first) drug administration in the current study.&#xD;
&#xD;
          -  Significant and/or acute illness within 5 days prior to (the first) drug&#xD;
             administration that may impact safety assessments, in the opinion of the Investigator.&#xD;
&#xD;
          -  Non-willingness to consume the high-fat breakfast (Part B only).&#xD;
&#xD;
          -  Unsuitable veins for infusion or blood sampling.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WanSeok Jeong, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Future Medicine Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renger Tiessen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA health Sciences</name>
      <address>
        <city>Groningen</city>
        <state>Gn</state>
        <zip>9728NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

